| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da54f7ebbd2d9d8a82f92aca4d1b4e48 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L29-16 |
| filingDate |
2006-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52ebad37233a4503d89db2a1dc64482a |
| publicationDate |
2008-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1951332-A1 |
| titleOfInvention |
Reduction of restenosis |
| abstract |
A method of reducing restenosis comprises administering to a patient a stent and reducing, shutting down or modifiying functioning of the immune system in a controlled manner. In a preferred embodiment T-cell depletion or T-cell modification is used for controlling the immune system. The T-cell depletor or T-cell modifier is administered either separately or as part of the stent. Alternatively, an ex-vivo procedure may be used. |
| priorityDate |
2005-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |